News | March 10, 2014

ImaCor’s hTEE Recognized for Hemodynamic Management Solution in Critical Care

ImaCor ClariTEE Zura EVO hTEE Ultrasound transesophageal TEE Cardiac

March 10, 2014 — ImaCor Inc., the developer of hemodynamic transesophageal echocardiography (hTEE) technology, announced four academic hTEE presentations. Physicians are publicly recognizing hTEE as a tool for managing complex ICU patients. Nick Fletcher, MBBS presented hTEE during the Heart Failure: State of the Art and Future Perspectives 5-day European Association of Cardio-Thoracic Surgery (EACTS) advanced module in Windsor, UK; Serban Bubenek, M.D., Ph.D described hTEE as the Advanced Hemodynamic Management solution at the Autumn Meeting of the European Society of Anesthesiology (ESA) in Timisoara, Romania; and Margarita Camacho, M.D. and Claudia Gidea, M.D. share hTEE case findings at the Tufts 6th Annual New England Heart Failure and Transplantation Network Conference in Waltham, Mass.

This follows an Oct. 8, 2013 session on hTEE Advanced Hemodynamic Management that was part of the scientific program at the 27th Annual Meeting of EACTS in Vienna, Austria. Speakers included A. Pieter Kappetein, M.D., Ph.D, Matthias Loebe M.D., Ph.D, and Simon Maltais M.D., Ph.D. During the 90-minute session, three videos of live hTEE case demonstrations were also presented from Vanderbilt University Medical Center, Nashville, Barnes-Jewish Hospital, St. Louis and Thomas Jefferson University Medical Center, Philadelphia.

hTEE is enabled through a miniature, disposable probe that can be placed in a patient for up to 72 hours to directly observe cardiac filling and function over time. It is easy-to-use and purpose-built for the ICU staff. With the growing population of older, sicker patients with multiple comorbidities, physicians recognize the benefits of hTEE’s continuous hemodynamic management to guide therapy. 

For more information: www.imacorinc.com


Related Content

News | Transesophageal Echo (TEE)

June 13, 2024 — Visura Technologies, Inc., a privately owned medical device company, has announced the TEECADE mini, an ...

Home June 13, 2024
Home
News | Transesophageal Echo (TEE)

May 29, 2024 — Congenital heart disease (CHD) is one of the most common congenital anomalies worldwide, which brings a ...

Home May 29, 2024
Home
News | Transesophageal Echo (TEE)

January 31, 2024 — Royal Philips, a global leader in health technology, announced that its latest TEE transducer ...

Home January 31, 2024
Home
News | Transesophageal Echo (TEE)

June 30, 2022 — Clarius Mobile Health, a leading provider of high-definition wireless ultrasound systems, and ImaCor Inc ...

Home June 30, 2022
Home
News | Transesophageal Echo (TEE)

June 7, 2022 — Visura Technologies, Inc., a privately-held medical device company dedicated to delivering state-of-the ...

Home June 07, 2022
Home
News | Transesophageal Echo (TEE)

February 5, 2019 – The American Society of Echocardiography (ASE) released a new document that provides a comprehensive ...

Home February 05, 2019
Home
Sponsored Content | Case Study | Transesophageal Echo (TEE) | Cyril Danielkutty B.E., Dillon Weiss, B.S., Chad A Kliger, M.D., M.S.

Transcatheter interventions have become a mainstay in cardiac care as treatments for structural and congenital heart ...

Home September 05, 2018
Home
Technology | Transesophageal Echo (TEE)

July 10, 2018 — Evanston, Ill.-based startup Visura Technologies has received 510(k) clearance from the U.S. Food and ...

Home July 10, 2018
Home
Technology | Transesophageal Echo (TEE)

June 20, 2017 — Dutch medical device company Stroke2prevent BV recently announced it has received U.S. Food and Drug ...

Home June 20, 2017
Home
News | Transesophageal Echo (TEE)

April 21, 2016 — CS Medical announced the release of their newest product designed to aid in the circle of care for ...

Home April 21, 2016
Home
Subscribe Now